Avibacterium paragallinarum causes infectious coryza in chickens. This bacterium secretes proteins of 110 kDa (a putative RTX protein) and 120 kDa. Expression of these proteins increases by the addition of CaCl(2), MgSO(4), MnSO(4), or ferric ammonium citrate and diminishes with CuSO(4) or ZnCl(2). Protein expression is optimal at 37 degrees C and pH 7.5. Mortality (90-100%) of chicken embryos was observed when secreted proteins (SPs) from A. paragallinarum reference or field isolates (serogroup A or C) were inoculated via yolk sac and was not observed when SPs from A. avium, a chicken respiratory tract indigenous bacterium, were inoculated. A. paragallinarum SPs could contain toxins responsible for the embryo deaths. Indeed, presence of the putative RTX protein of 110 kDa was confirmed by Western blotting with antibodies against the Actinobacillus pleuropneumoniae RTX ApxI, a closely related RTX protein.

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1428.007DOI Listing

Publication Analysis

Top Keywords

rtx protein
12
secreted proteins
8
avibacterium paragallinarum
8
110 kda
8
putative rtx
8
proteins avibacterium
4
paragallinarum
4
paragallinarum lethal
4
lethal chicken
4
chicken embryo
4

Similar Publications

Background/objectives: Anti-MAG polyneuropathy is a demyelinating peripheral neuropathy associated with IgM monoclonal gammopathies, particularly MGUS (monoclonal gammopathy of undetermined significance) and Waldenström macroglobulinemia. It is characterized by a subacute onset of distal sensory symptoms, with distal motor dysfunction typically appearing only in the later stages of the disease. The condition is caused by the presence of autoantibodies directed against myelin-associated glycoprotein, a structural protein of myelin.

View Article and Find Full Text PDF

is the causative agent of atypical vibriosis in salmonids cultured in Chile. While extensive research provides insights into through phenotypic, antigenic, and genetic typing, as well as various virulence mechanisms, proteomic characterization remains largely unexplored. This study aimed to advance the proteomic knowledge of Chilean Vo-LM-18 and its OMVs, which have known virulence.

View Article and Find Full Text PDF

We studied the effect of urinary urea concentration on the hemolysin production and cytotoxicity of the uropathogenic Morganella morganii strain MM 190. The highest hemolytic activity of M. morganii cultivated in urine with low urea concentration (23 and 82 mmol/liter) was observed between 3rd and 4th hours of post-inoculation, while in urine with standard urea level (117 mmol/liter), the activity was observed at 5th hour of post-inoculation.

View Article and Find Full Text PDF

Objective: Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to compare the efficacy of rituximab (RTX) followed by belimumab or telitacicept in a real-world cohort.

Methods: A total of 49 refractory lupus nephritis patients were enrolled from four independent centres, subsequently categorised into two treatment groups: belimumab group (n=35) and telitacicept group (n=14) based on their treatment following RTX.

View Article and Find Full Text PDF
Article Synopsis
  • This study tested rituximab (RTX) on patients with primary membranous nephropathy (PMN) who were dependent on calmodulin inhibitors (CNIs) and not fully in remission.
  • Among 36 patients, those who were drug-dependent showed a significant reduction in proteinuria and improved remission rates after 12 months of RTX therapy, with complete remission increasing from 10% to 70%.
  • The results indicated that RTX not only helped patients overcome CNI dependency but also led to significant immunological improvements while minimizing the risks of adverse effects.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!